EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RASopathy-associated CBL germline mutations cause aberrant ubiquitylation and trafficking of EGFR



RASopathy-associated CBL germline mutations cause aberrant ubiquitylation and trafficking of EGFR



Human Mutation 35(11): 1372-1381



Noonan syndrome, a congenital disorder comprising a characteristic face, short stature, heart defects, learning difficulties, and a predisposition to malignancies, is caused by heterozygous germline mutations in genes encoding components of RAS-MAPK signaling pathways. Mutations in the CBL tumor suppressor gene have been reported in patients with a Noonan syndrome-like phenotype. CBL encodes a multivalent adaptor protein with ubiquitin ligase activity, which promotes ubiquitylation and vesicle-mediated internalization and degradation of the epidermal growth factor (EGF) receptor (EGFR). We investigated the functional consequences of disease-associated CBL amino acid changes p.K382E, p.D390Y, and p.R420Q on ligand-induced EGFR trafficking. Expression of CBL(K382E), CBL(D390Y), or CBL(R420Q) in COS-7 cells resulted in increased levels of surface EGFR and reduced amounts of intracellular EGFR; both consequences indicate ineffective EGFR internalization. Accordingly, receptor-mediated uptake of EGF was decreased. Furthermore, the p.K382E, p.D390Y, and p.R420Q lesions impaired CBL-mediated EGFR ubiquitylation and degradation. Together, these data indicate that pathogenic CBL mutations severely affect vesicle-based EGFR trafficking. Since we detected enhanced ERK phosphorylation in cells expressing mutant CBL, we conclude that aberrant EGFR trafficking contributes to augmented RAS-MAPK signaling, the common trait of Noonan syndrome and related RASopathies. Thus, our data suggest that EGFR trafficking is a novel disease-relevant regulatory level in the RASopathy network.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333515

Download citation: RISBibTeXText

PMID: 25178484

DOI: 10.1002/humu.22682



Related references

Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Research 71(7): 2423-2427, 2011

Endocytosis of Ubiquitylation-Deficient EGFR Mutants via Clathrin-Coated Pits is Mediated by Ubiquitylation. Traffic 16(11): 1137-1154, 2016

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations. Clinical Advances in Hematology & Oncology 14(1): 41, 44-5, 2016

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. Journal of the National Comprehensive Cancer Network 12(1): 6-11; Quiz 11, 2014

Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. Bmc Cell Biology 10(): 84-84, 2010

A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking. Plos One 12(5): E0173565-E0173565, 2017

Screening for germline EGFR T790M mutations through lung cancer genotyping. Journal of Thoracic Oncology 7(6): 1049-1052, 2012

EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. Journal of Thoracic Oncology 3(7): 805-805, 2008

EGFR mutations and response to gefitinib or erlotinib: A meta-analysis based on a comprehensive EGFR somatic mutation database ( www.egfr-mutations.org ). Journal of Clinical Oncology 26(15_suppl): 22049-22049, 2016

The Rasopathy family: Consequences of germline activation of the RAS/MAPK pathway. Endocrine Reviews, 2018

Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer 17(2): E5-11, 2015

Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Human Mutation 32(1): 33-43, 2011

Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. Journal of Thoracic Oncology 9(4): 456-463, 2015

Childhood Rhabdomyosarcoma in Association With a RASopathy Clinical Phenotype and Mosaic Germline SOS1 Duplication. Journal of Pediatric Hematology/Oncology 38(8): E278-E282, 2016

Aberrant Expression of Rb and pRb-780, pRb-795 in Lung Adenocarcinoma Patients with EGFR Mutations and Their Clinical Significance. Zhongguo Fei Ai Za Zhi 20(5): 312-317, 2017